US Patent Granted for Verona Pharma’s RPL554
News Jan 01, 2013
Verona Pharma plc has announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554.
The patent is the fourth patent issued for RPL554 and related compounds in the US.
RPL554, Verona Pharma's lead drug candidate, is a dual phosphodiesterase 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties.
RPL554 is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
The Company is currently carrying out clinical trials of the drug to further characterize its bronchodilator and anti-inflammatory effects.
Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We are growing the intellectual property portfolio around the RPL554 programme and the issue of this new US Patent strengthens and harmonizes our international patent estate around RPL554 and provides exclusivity in one of the world’s leading pharmaceutical markets. We continue to develop our intellectual property rights as this is a key part of Verona Pharma’s strategy.”
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017